| First Author | Leung RKC | Year | 2020 |
| Journal | Semin Cancer Biol | Volume | 67 |
| Issue | Pt 1 | Pages | 24-29 |
| PubMed ID | 31698089 | Mgi Jnum | J:299462 |
| Mgi Id | MGI:6477728 | Doi | 10.1016/j.semcancer.2019.11.001 |
| Citation | Leung RKC, et al. (2020) Diverse pathogenetic roles of SOX genes in acute myeloid leukaemia and their therapeutic implications. Semin Cancer Biol 67(Pt 1):24-29 |
| abstractText | Acute myeloid leukaemia (AML) is a heterogeneous group of diseases with diverse pathogenetic pathways. When treated uniformly with conventional chemotherapy and allogeneic haematopoietic stem cell transplantation (HSCT), it showed variable clinical outcome and prognosis. Members of the SOX [Sry-related high-mobility group (HMG) box] gene family are involved in diverse embryonic and oncogenic processes. The roles of SOX genes in AML are not entirely clear but emerging evidence, including that arising from studies in solid-cancers, showed that SOX genes can function as tumour suppressors or oncogenes and may be involved in key pathogenetic pathways in AML involving C/EBPalpha mutations, activation of beta-catenin/Wnt and Hedgehog pathways and aberrant TP53 signals. Recent data based on genomics and proteomics have identified key interactions between SOX genes and partnering proteins of pathogenetic significance. The observations illustrated the principles and feasibilities of developing lead molecules of potential therapeutic values. Studying the diverse pathogenetic roles of SOX genes in AML may shed lights to the heterogeneity of AML and generate information that can be translated into novel therapeutic strategies. |
